Table 2.
Comparison of protein expression features in hepatic steatosis patients and the control group
| Total hepatic steatosis | NAFLD | AFLD | Control | *P value | |
|---|---|---|---|---|---|
| (N = 29) | (n = 18) | (n = 11) | (N = 38) | ||
| Protein expression in hepatocytes | |||||
| mTOR, positive | 16 (55%) | 14 (78%) | 2 (18%) | 1 (3%) | < 0.001 |
| pSTAT3, positive | 11 (38%) | 3 (17%) | 8 (73%) | 4 (11%) | 0.007 |
| pERK, positive | 8 (28%) | 4 (22%) | 4 (36%) | 1 (3%) | 0.003 |
| Estrogen-receptor α, positive | 29 (100%) | 18 (100%) | 11 (100%) | 0 | < 0.001 |
| Focal positive | 7 (24%) | 0 | 7 (64%) | 0 | |
| Diffuse positive | 22 (76%) | 18 (100%) | 4 (36%) | 0 | |
| Protein expression in hepatic stellate cells | |||||
| pSTAT3, positive | 5 (17%) | 0 | 5 (45%) | 2 (5%) | 0.055 |
| pERK, positive | 29 (100%) | 18 (100%) | 11 (100%) | 3 (8%) | < 0.001 |
NAFLD non-alcoholic fatty liver disease
AFLD alcoholic fatty liver disease
Control, non-neoplastic hepatosytes from 16 cases of biliary cyst and 22 cases of hepatolithiasis
* P value between total hepatic steatosis group (N = 29) and the control group (N = 38)